ARTBIO
67 employees
Biotech/Pharma
Series B · $245.0M
Open positions (2)
Company details
Team Size67
IndustryBiotech/Pharma
Funding
Total raised
$245.0M
Last stage
Series B
Investors
Omega Funds
Total raised
$245.0M
Last stage
Series B
Investors
Roy H. Larsen
PhD; co-invented Xofigo (acquired by Bayer via Algeta), the first-ever metabolically targeted alpha therapy; long-standing researcher at the University of Oslo and Norway's Radium Hospital.
Øyvind Bruland
MD; co-invented Xofigo with Roy Larsen; veteran radiopharmaceutical researcher based in Oslo, Norway; collaborated with F-Prime and Radforsk to co-found ARTBIO in 2021.
Emanuele Ostuni
PhD; formerly Head of Europe for Cell and Gene Therapy at Novartis Oncology; joined ARTBIO in early 2022 to build the company and advance its proprietary technology.
LinkedInNo applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.